Xin Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2924328/publications.pdf

Version: 2024-02-01

100 papers	4,927 citations	109321 35 h-index	114465 63 g-index
104 all docs	104 docs citations	104 times ranked	7180 citing authors

#	Article	IF	Citations
1	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 2019, 35, 428-440.e5.	16.8	571
2	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clinical Cancer Research, 2019, 25, 5002-5014.	7.0	269
3	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metabolism, 2021, 33, 51-64.e9.	16.2	211
4	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Research, 2016, 18, 33.	5.0	176
5	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Research, 2016, 76, 2105-2114.	0.9	168
6	Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex. Cell, 2016, 165, 331-342.	28.9	163
7	Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Scientific Reports, 2017, 7, 45411.	3.3	149
8	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Research, 2021, 31, 178-186.	12.0	146
9	Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI. EBioMedicine, 2019, 49, 341-353.	6.1	123
10	Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Research, 2020, 48, 3638-3656.	14.5	105
11	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metabolism, 2022, 34, 581-594.e8.	16.2	105
12	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Research, 2022, 32, 477-490.	12.0	101
13	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nature Communications, 2018, 9, 1357.	12.8	100
14	The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Science Advances, 2019, 5, eaat9820.	10.3	95
15	An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy. PLoS ONE, 2014, 9, e111886.	2.5	95
16	The spectrum of BRCA mutations and characteristics of BRCAâ€associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by nextâ€generation sequencing. International Journal of Cancer, 2017, 141, 129-142.	5.1	89
17	Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. Nature Communications, 2019, 10, 1637.	12.8	86
18	Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. Cancer Research, 2015, 75, 1504-1515.	0.9	71

#	Article	IF	Citations
19	Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1653-1662.	7.0	68
20	PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Research, 2018, 78, 3190-3206.	0.9	62
21	Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clinical Cancer Research, 2016, 22, 4859-4869.	7.0	60
22	SSBP1 Suppresses TGFÎ²-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling. Cancer Research, 2016, 76, 952-964.	0.9	59
23	The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017. Frontiers in Oncology, 2020, 10, 650.	2.8	56
24	Co-Expression Network Analysis Identified Gene Signatures in Osteosarcoma as a Predictive Tool for Lung Metastasis and Survival. Journal of Cancer, 2019, 10, 3706-3716.	2.5	49
25	Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Research and Treatment, 2019, 173, 225-237.	2.5	49
26	Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers. Molecular Therapy, 2021, 29, 2350-2365.	8.2	49
27	High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. PLoS ONE, 2015, 10, e0140572.	2.5	48
28	Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget, 0, 7, 41285-41293.	1.8	47
29	Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism. PLoS ONE, 2015, 10, e0144441.	2.5	46
30	Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. OncoTargets and Therapy, 2016, 9, 1801.	2.0	45
31	Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing. PLoS ONE, 2015, 10, e0125571.	2.5	44
32	CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. Theranostics, 2018, 8, 2549-2564.	10.0	44
33	Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-Î²/SMAD signaling. Oncotarget, 2015, 6, 16352-16365.	1.8	42
34	High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget, 2016, 7, 64900-64909.	1.8	41
35	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nature Communications, 2020, 11, 5679.	12.8	41
36	Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. Scientific Reports, 2018, 8, 2225.	3.3	38

#	Article	IF	Citations
37	IL6 blockade potentiates the anti-tumor effects of Î³-secretase inhibitors in Notch3-expressing breast cancer. Cell Death and Differentiation, 2018, 25, 330-339.	11.2	38
38	Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. Oncotarget, 2015, 6, 22227-22238.	1.8	37
39	Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Management and Research, 2018, Volume 10, 5937-5950.	1.9	35
40	Positive expression of miR-361-5p indicates better prognosis for breast cancer patients. Journal of Thoracic Disease, 2016, 8, 1772-1779.	1.4	34
41	Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Medicine, 2018, 7, 4156-4169.	2.8	34
42	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Molecular Cancer, 2022, 21, 84.	19.2	34
43	Interplay between MÃ¼ller cells and microglia aggravates retinal inflammatory response in experimental glaucoma. Journal of Neuroinflammation, 2021, 18, 303.	7.2	34
44	The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. Cancer Letters, 2016, 377, 87-96.	7.2	32
45	MicroRNAâ€493 is a prognostic factor in tripleâ€negative breast cancer. Cancer Science, 2018, 109, 2294-2301.	3.9	32
46	The 3â€²UTR signature defines a highly metastatic subgroup of triple-negative breast cancer. Oncotarget, 2016, 7, 59834-59844.	1.8	32
47	Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. Cell Research, 2019, 29, 832-845.	12.0	31
48	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. Clinical Cancer Research, 2019, 25, 3658-3672.	7.0	31
49	Clinico-Pathological Features and Prognosis of Invasive Micropapillary Carcinoma Compared to Invasive Ductal Carcinoma: A Population-Based Study from China. PLoS ONE, 2014, 9, e101390.	2.5	30
50	Association between socioeconomic factors at diagnosis and survival in breast cancer: A populationâ€based study. Cancer Medicine, 2020, 9, 1922-1936.	2.8	28
51	Prognostic Value of Myeloid Differentiation Primary Response 88 and Toll-Like Receptor 4 in Breast Cancer Patients. PLoS ONE, 2014, 9, e111639.	2.5	27
52	Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. Biochemical and Biophysical Research Communications, 2015, 458, 816-822.	2.1	27
53	Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers. Theranostics, 2020, 10, 10531-10547.	10.0	27
54	Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer. Oncotarget, 2015, 6, 43363-43374.	1.8	26

#	Article	IF	Citations
55	In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Science Advances, 2022, 8, .	10.3	26
56	Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks. Genome Research, 2019, 29, 270-280.	5.5	25
57	PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 5491-5505.	0.9	25
58	High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer. Cancer Cell International, 2019, 19, 165.	4.1	24
59	Protein C receptor stimulates multiple signaling pathways in breast cancer cells. Journal of Biological Chemistry, 2018, 293, 1413-1424.	3.4	23
60	In-line phase-contrast and grating-based phase-contrast synchrotron imaging study of brain micrometastasis of breast cancer. Scientific Reports, 2015, 5, 9418.	3.3	22
61	Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. Tumor Biology, 2016, 37, 1279-1287.	1.8	22
62	Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer. Theranostics, 2020, 10, 11092-11109.	10.0	22
63	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 884-892.	6.3	21
64	Ciliary neurotrophic factor receptor Î± subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. Hepatology, 2008, 47, 1298-1308.	7.3	19
65	Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells. Oncogene, 2019, 38, 5778-5791.	5.9	19
66	Tumor necrosis factor-alpha aggravates gliosis and inflammation of activated retinal MÃ¼ller cells. Biochemical and Biophysical Research Communications, 2020, 531, 383-389.	2.1	19
67	Deregulation of RGS17 Expression Promotes Breast Cancer Progression. Journal of Cancer, 2015, 6, 767-775.	2.5	18
68	Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer. Oncotarget, 2016, 7, 53895-53902.	1.8	18
69	Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. Scientific Reports, 2016, 6, 24037.	3.3	17
70	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget, 2015, 6, 22985-22995.	1.8	16
71	Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. BMC Cancer, 2018, 18, 1085.	2.6	16
72	Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer. Cancer Management and Research, 2018, Volume 10, 5881-5894.	1.9	14

#	Article	IF	Citations
73	ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. OncoTargets and Therapy, 2014, 7, 1083.	2.0	13
74	Integrative 3â€² Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. Oncologist, 2019, 24, 22-30.	3.7	13
75	Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer. Scientific Reports, 2019, 9, 6032.	3.3	13
76	Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 574813.	2.8	13
77	Integration of wholeâ€genome sequencing and functional screening identifies a prognostic signature for lung metastasis in tripleâ€negative breast cancer. International Journal of Cancer, 2019, 145, 2850-2860.	5.1	12
78	Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China. OncoTargets and Therapy, 2016, 9, 2287.	2.0	11
79	Dopamine D2 Receptor-Mediated Modulation of Rat Retinal Ganglion Cell Excitability. Neuroscience Bulletin, 2020, 36, 230-242.	2.9	11
80	Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems. Breast, 2020, 49, 93-100.	2.2	11
81	Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China. BMC Cancer, 2020, 20, 244.	2.6	11
82	P2X7/P2X4 Receptors Mediate Proliferation and Migration of Retinal Microglia in Experimental Glaucoma in Mice. Neuroscience Bulletin, 2022, 38, 901-915.	2.9	11
83	Development and Validation of Nomograms for Predicting Overall and Breast Cancerâ€“Specific Survival in Young Women with Breast Cancer: A Population-Based Study. Translational Oncology, 2018, 11, 1334-1342.	3.7	10
84	Outcomes and risk of subsequent breast events in breastâ€conserving surgery patients with BRCA1 and BRCA2 mutation. Cancer Medicine, 2020, 9, 1903-1910.	2.8	10
85	The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer. Oncotarget, 2016, 7, 14951-14962.	1.8	10
86	Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients. Journal of Cancer, 2022, 13, 744-751.	2.5	10
87	Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells. Oncology Letters, 2014, 8, 2086-2092.	1.8	9
88	No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. Journal of Surgical Oncology, 2018, 118, 928-935.	1.7	9
89	Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma. European Journal of Surgical Oncology, 2018, 44, 1703-1707.	1.0	9
90	Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma. Experimental Eye Research, 2021, 204, 108449.	2.6	9

#	Article	IF	Citations
91	High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer. Journal of Thoracic Disease, 2017, 9, 1002-1011.	1.4	7
92	Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. Annals of Translational Medicine, 2020, 8, 1417-1417.	1.7	7
93	Largeâ€scale genomic sequencing reveals adaptive opportunity of targeting mutatedâ€PI3Kî± in early and advanced HER2â€positive breast cancer. Clinical and Translational Medicine, 2021, 11, e589.	4.0	6
94	<scp>RNA</scp> binding protein <scp>POP7</scp> regulates <scp>ILF3 mRNA</scp> stability and expression to promote breast cancer progression. Cancer Science, 2022, 113, 3801-3813.	3.9	6
95	Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. Scientific Reports, 2017, 7, 1134.	3.3	5
96	A recessive variant of XRCC4 predisposes to non-BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. Oncotarget, 2014, 5, 12218-12232.	1.8	5
97	Nomogram for Predicting Breast Cancer-Specific Mortality of Elderly Women with Breast Cancer. Medical Science Monitor, 2020, 26, e925210.	1.1	3
98	Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women. Oncotarget, 2016, 7, 9759-9772.	1.8	3
99	KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1. American Journal of Cancer Research, 2020, 10, 3302-3315.	1.4	2
100	Breast Cancer: IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15â€Dependent BMI1 Stability (Adv. Sci. 1/2020). Advanced Science, 2020, 7, 2070002.	11.2	0